Literature DB >> 19295432

Acute pain in children and adults with sickle cell disease: management in the absence of evidence-based guidelines.

Joshua J Field1, Jessica E Knight-Perry, Michael R Debaun.   

Abstract

PURPOSE OF REVIEW: Acute, vaso-occlusive pain is the most characteristic complication of sickle cell disease (SCD). Although there has been rigorous work examining the pathogenesis of vaso-occlusion, fewer studies have focused on approaches to the clinical management of acute pain. In this review, we will examine the epidemiology and management strategies of acute pain events and we will identify limitations in the best available studies. RECENT
FINDINGS: Most acute pain events in adults with SCD are managed at home without physician contact. Prior descriptions of the natural history of pain episodes from the Cooperative Study of Sickle Cell Disease relied on physician contact, limiting the generalizability of these findings to current practice. Patient-controlled analgesia has replaced on-demand therapy to become the standard for management of severe pain events in children and adults with SCD requiring hospital admission.
SUMMARY: Unfortunately, most clinical practice guidelines for the management of acute pain are not based on randomized clinical trials. As a result, our practice of pain management is primarily limited to expert opinion and inferences from observational studies. Additional clinical trials in management of acute pain in children and adults with SCD are critical for the development of evidence-based guidelines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19295432     DOI: 10.1097/MOH.0b013e328329e167

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  8 in total

1.  A 19-year-old woman with sickle cell disease and pain.

Authors:  Richard Ward; Ewurabena Simpson; Madeleine Verhovsek
Journal:  CMAJ       Date:  2016-02-01       Impact factor: 8.262

2.  Dexmedetomidine ameliorates nocifensive behavior in humanized sickle cell mice.

Authors:  Gabriela Calhoun; Li Wang; Luis E F Almeida; Nicholas Kenyon; Nina Afsar; Mehdi Nouraie; Julia C Finkel; Zenaide M N Quezado
Journal:  Eur J Pharmacol       Date:  2015-02-25       Impact factor: 4.432

3.  Changes in Conjunctival Hemodynamics Predict Albuminuria in Sickle Cell Nephropathy.

Authors:  Ali Kord Valeshabad; Justin Wanek; Santosh L Saraf; Bruce I Gaynes; Victor R Gordeuk; Robert E Molokie; Mahnaz Shahidi
Journal:  Am J Nephrol       Date:  2015-08-05       Impact factor: 3.754

4.  Intravenous magnesium for pediatric sickle cell vaso-occlusive crisis: methodological issues of a randomized controlled trial.

Authors:  Oluwakemi Badaki-Makun; J Paul Scott; Julie A Panepinto; T Charles Casper; Cheryl A Hillery; J Michael Dean; David C Brousseau
Journal:  Pediatr Blood Cancer       Date:  2014-01-17       Impact factor: 3.167

5.  Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease.

Authors:  Kathy A Sheehy; Julia C Finkel; Deepika S Darbari; Michael F Guerrera; Zenaide M N Quezado
Journal:  Pain Pract       Date:  2015-07-23       Impact factor: 3.183

6.  Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management.

Authors:  Cheedy Jaja; Latanya Bowman; Leigh Wells; Niren Patel; Hongyan Xu; Matt Lyon; Abdullah Kutlar
Journal:  Clin Transl Sci       Date:  2015-02-02       Impact factor: 4.689

7.  CYP2C9 allelic variants and frequencies in a pediatric sickle cell disease cohort: implications for NSAIDs pharmacotherapy.

Authors:  Cheedy Jaja; Niren Patel; Stuart A Scott; Robert Gibson; Abdullah Kutlar
Journal:  Clin Transl Sci       Date:  2014-05-29       Impact factor: 4.689

8.  Oral morphine protocol evaluation for the treatment of vaso-occlusive crisis in paediatric sickle cell patients.

Authors:  Hugo Paquin; Evelyne D Trottier; Nancy Robitaille; Yves Pastore; Marie-Joelle Dore Bergeron; Benoit Bailey
Journal:  Paediatr Child Health       Date:  2018-05-31       Impact factor: 2.253

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.